当前位置: 首页 >> 检索结果
321. Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
Xie Y, Choi T, Al-Aly Z. Postacute sequelae of SARS-CoV-2 infection in the pre-Delta, Delta, and Omicron eras. N Engl J Med. 2024;391:515-525. 39018527.
322. Response of Human Epidermal Growth Factor Receptor 2-Expressing Prostate Cancer to Trastuzumab Deruxtecan.
作者: Coen J Lap.;Rithika Rajendran.;Jose Manuel Martin.;Manisha Uppal.;Asha Escobar.;Angela M Heiraty.;Fayez Estephan.;Winnie Hahn.;Ramesh Subrahmanyam.;Victor E Nava.;Maneesh Jain.
来源: Ann Intern Med. 2024年177卷12期1738-1741页 324. Ensuring Safe Practice by Late Career Physicians: Institutional Policies and Implementation Experiences.
作者: Andrew A White.;Thomas H Gallagher.;Paulina H Osinska.;Daniel B Kramer.;Kelly Davis Garrett.;Michelle M Mello.
来源: Ann Intern Med. 2024年177卷12期1702-1710页
Late career physicians (LCPs; physicians working beyond age 65 to 75 years) may be at higher risk for delivering unsafe care. To oversee LCPs, some health care organizations (HCOs) have adopted LCP policies requiring cognitive, physical, and practice performance screening assessments. Despite recent controversies, little is known about the content and implementation of such policies.
325. In active ulcerative colitis, risankizumab induced and maintained remission.
Louis E, Schreiber S, Panaccione R, et al; INSPIRE and COMMAND Study Group. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA. 2024;332:881-897. 39037800.
326. In symptomatic knee OA, adding oral methotrexate to usual analgesia reduced pain at 6 mo.
Kingsbury SR, Tharmanathan P, Keding A, et al. Pain reduction with oral methotrexate in knee osteoarthritis: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2024;177:1145-1156. 39074374.
327. In older adults receiving high-risk medications, a deprescribing intervention did not reduce falls at 18 mo.
Phelan EA, Williamson BD, Balderson BH, et al. Reducing central nervous system-active medications to prevent falls and injuries among older adults: a cluster randomized clinical trial. JAMA Netw Open. 2024;7:e2424234. 39052289.
328. In older inpatients with polypharmacy, medication optimization did not improve outcomes at 48 wk.
Ie K, Hirose M, Sakai T, et al. Medication optimization protocol efficacy for geriatric inpatients: a randomized clinical trial. JAMA Netw Open. 2024;7:e2423544. 39078632.
329. In adults with TBI and anemia, liberal vs. restrictive RBC transfusion did not reduce unfavorable neurologic outcomes by 10% at 6 mo.
Turgeon AF, Fergusson DA, Clayton L, et al; HEMOTION Trial Investigators on behalf of the Canadian Critical Care Trials Group, the Canadian Perioperative Anesthesia Clinical Trials Group, and the Canadian Traumatic Brain Injury Research Consortium. Liberal or restrictive transfusion strategy in patients with traumatic brain injury. N Engl J Med. 2024;391:722-735. 38869931.
330. In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12:545-557. 38991584.
332. Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.
作者: Jadine Scragg.;Alice Hobson.;Lia Willis.;Kathryn S Taylor.;Sharon Dixon.;Susan A Jebb.
来源: Ann Intern Med. 2024年177卷12期1664-1674页
Polycystic ovary syndrome (PCOS) is common in women of reproductive age and is associated with obesity. Clinical guidelines recommend weight loss, but the impact on the clinical manifestations of PCOS is unclear.
333. In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4.
Lopes RD, Granger CB, Wojdyla DM, et al. Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol. 2024;84:354-364. 39019530.
334. In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.
Lingvay I, Deanfield J, Kahn SE, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care. 2024;47:1360-1369. 38907684.
335. In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12:447-461. 38768620.
337. A New Horizon: The Promise of the National Institutes of Health's Landmark Designation of Persons With Disabilities as a Population With Health Disparities.338. Risk for Financial Precarity From Hospitalization: Implications for Targeting Financial Assistance in Medicare.
作者: Paula Chatterjee.;Eliza Macneal.;Syama R Patel.;Eric T Roberts.
来源: Ann Intern Med. 2024年177卷12期1601-1609页
High out-of-pocket costs in Medicare may leave many beneficiaries in financial precarity. Beneficiaries with modest incomes are often ineligible for Medicaid (which covers most out-of-pocket Medicare costs) and may have insufficient resources to pay an unexpected health care bill. This has prompted calls to improve financial protections, but the target population remains uncharacterized.
|